Inflammation: A common pathway in cardiovascular diseases

Dialogues in Cardiovascular Medicine

Volumn 8, Issue 2, 2003, Pages 59-73

  Libby, Peter ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute myocardial infarction; Atherosclerosis; Cardiovascular disease; Cytokine; Host defense; Immune response; Inflammation; Inflammatory factor; Treatment

Indexed keywords

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; HOST RESISTANCE; HUMAN; IMMUNITY; INFLAMMATION; INFLAMMATORY DISEASE; OUTCOMES RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW;

EID: 0344364575     PISSN: 12729949     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Virchow R. Cellular Pathology. London, UK: John Churchill; 1858.
2. Chernyak L, Tauber AI. The birth of immunology: Metchnikoff, the embryologist. Cell Immunol. 1988;117:218-233.
3. Libby P. Changing concepts of atherogenesis. J Intern Med. 2000;247:349-358.
4. Bevilacqua MP, Pober JS, Majeau GR, Cotran RS, Gimbrone MA Jr. Interleukin-1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes and related leukocyte cell lines. J Clin Invest. 1985;76:2003-2011.
5. Frenette PS, Wagner DD. Insights into selectin function from knockout mice. Thromb Haemost. 1997;78:60-64.
6. Wang J, Springer TA. Structural specializations of immunoglobulin superfamily members for adhesion to integrins and viruses. Immunol Rev. 1998;163:197-215.
7. Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev. 1998;9:9-23.
8. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med. 1998;338:436-445.
9. Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103:1718-1720.
10. Nemerson Y, Giesen PL. Some thoughts about localization and expression of tissue factor. Blood Coagulation Fibrinol. 1998;9:S45-S47.
11. Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Cell Biol. 1983;80:2956-2960.
12. Nathan C, Shiloh MU. Reactive oxygen and nitrogen intermediates in the relationship between mammalian hosts and microbial pathogens. Proc Natl Acad Sci USA. 2000;97:8841-8848.
13. Fadok VA, Henson PM. Apoptosis: getting rid of the bodies. Curr Biol. 1998;8:R693-R695.
14. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res. 1995;77:863-868.
15. Libby P, Geng YJ, Aikawa M, et al. Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol. 1996;7:330-335.
16. Krieger M. The other side of scavenger receptors: pattern recognition for host defense. Curr Opin Lipidol. 1997;8:275-280.
17. Medzhitov R, Janeway CA Jr. Innate immune induction of the adaptive immune response. Cold Spring Harb Symp Quant Biol. 1999;64:429-435.
18. Kimbrell DA, Beutler B. The evolution and genetics of innate immunity. Nat Rev Genet. 2001;2:256-267.
19. Walport MJ. Complement. First of two parts. N Engl J Med. 2001;344:1058-1066.
20. Walport MJ. Complement. Second of two parts. N Engl J Med. 2001;344:1140-1144.
21. Libby P, Ross R. Cytokines and growth regulatory molecules. In: Fuster V, Ross R, Topol E, eds. Atherosclerosis and Coronary Artery Disease. New York, NY: Lippincott-Raven; 1996:585-594.
22. Dinarello C. The interleukin-1 family: 10 years of discovery. FASEB J. 1994;8:1314-1325.
23. Thornberry NA, Bull HG, Calaycay JR, et al. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. Nature. 1992;356:768-774.
24. Collins T, Cybulsky MI. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest. 2001;107:255-264.
25. Dinarello CA, Ikejima T, Warner SJC, et al. Interleukin-1 induces interleukin-1. I. Induction of circulating interleukin-1 in rabbits in vivo and in human mononuclear cells in vitro. J Immunol. 1987;139:1902-1910.
26. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-245.
27. Loppnow H, Libby P. Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest. 1990;85:731-738.
28. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulation. 1999;100:1148-1150.
29. Van Lenten B, Hama SY, de Beer F, et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest. 1995;96:2758-2767.
30. Collins T, Korman AJ, Wake CT, et al. Immune interferon activates multiple class II major histocompatibility complex genes and the associated invariant chain gene in human endothelial cells and dermal fibroblasts. Proc Natl Acad Sci USA. 1984;81:4917-4921.
31. Schonbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol. 2000;32:687-693.
32. Clark WR. Immunology. The hole truth about perforin. Nature. 1994;369:16-17.
33. Shaw G. The Doctor's Dilemma. Baltimore, Md: Penguin Books, Inc; 1911.
34. Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 1998;9:441-448.
35. Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84:489-497.
36. Kol A, Libby P. The mechanisms by which infectious agents may contribute to atherosclerosis and its clinical manifestations. Trends Cardiovasc Med. 1998;8:191-199.
37. Clinton S, Underwood R, Sherman M, Kufe D, Libby P. Macrophage-colony stimulating factor gene expression in vascular cells and in experimental and human atherosclerosis. Am J Pathol. 1992;140:301-316.
38. Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest. 2001;107:1255-1262.
39. Hajjar DP, Haberland ME. Lipoprotein trafficking in vascular cells. Molecular Trojan horses and cellular saboteurs. J Biol Chem. 1997;272:22975-22978.
40. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997;386:292-296.
41. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000;105:1049-1056.
42. Shimizu K, Sugiyama S, Aikawa M, et al. Host bone-marrow cells are a source of donor intimal smooth-muscle-like cells in murine aortic transplant arteriopathy. Nat Med. 2001;7:738-741.
43. Jonasson L, Holm J, Skalli O, Bondjers G, Hansson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986;6:131-138.
44. Geng YJ, Libby P. Evidence for apoptosis in advanced human atheroma. Co-localization with interleukin-1β-converting enzyme. Am J Pathol. 1995;147:251-266.
45. Davies MJ. Stability and instability: the two faces of coronary atherosclerosis. The Paul Dudly White Lecture, 1995. Circulation. 1996;94:2013-2020.
46. Lee R, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997;17:1859-1867.
47. Mach F, Schoenbeck U, Bonnefoy JY, Pober J, Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factor. Circulation. 1997;96:396-399.
48. Libby P, Aikawa M. Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med. 2002;8:1257-1262.
49. Marx N, Libby P, Plutzky J. Peroxisome proliferator-activated receptors (PPARs) and their role in the vessel wall: possible mediators of cardiovascular risk? J Cardiovasc Risk. 2001;8:203-210.
50. Schoenbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.